These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 11693314

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
    Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, Perelson AS.
    J Infect Dis; 2003 Nov 15; 188(10):1498-507. PubMed ID: 14624375
    [Abstract] [Full Text] [Related]

  • 3. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team.
    JAMA; 2004 Dec 15; 292(23):2839-48. PubMed ID: 15598915
    [Abstract] [Full Text] [Related]

  • 4. Delaying HCV treatment in HIV-positive patients.
    Carter M.
    IAPAC Mon; 2005 May 15; 11(5):147. PubMed ID: 16201045
    [No Abstract] [Full Text] [Related]

  • 5. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J.
    J Antimicrob Chemother; 2007 Dec 15; 60(6):1347-54. PubMed ID: 17938129
    [Abstract] [Full Text] [Related]

  • 6. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B, Kottilil S.
    AIDS; 2007 Sep 12; 21(14):1855-65. PubMed ID: 17721093
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of hepatitis C virus infection].
    Zeuzem S.
    Praxis (Bern 1994); 2005 May 04; 94(18):721-6. PubMed ID: 15938383
    [Abstract] [Full Text] [Related]

  • 8. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
    Pivert A, Payan C, Morand P, Fafi-Kremer S, Deshayes J, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F.
    J Clin Microbiol; 2006 Feb 04; 44(2):417-22. PubMed ID: 16455894
    [Abstract] [Full Text] [Related]

  • 9. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H.
    Intervirology; 2007 Feb 04; 50(5):361-8. PubMed ID: 17728547
    [Abstract] [Full Text] [Related]

  • 10. Management of hepatitis C in HIV infected and other immunocompromised individuals.
    Seth AK.
    Trop Gastroenterol; 2006 Feb 04; 27(3):111-7. PubMed ID: 17310553
    [Abstract] [Full Text] [Related]

  • 11. Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
    Hua S, Vigano S, Tse S, Zhengyu O, Harrington S, Negron J, Garcia-Broncano P, Marchetti G, Genebat M, Leal M, Resino S, Ruiz-Mateos E, Lichterfeld M, Yu XG.
    Clin Infect Dis; 2018 Jun 01; 66(12):1910-1917. PubMed ID: 29272392
    [Abstract] [Full Text] [Related]

  • 12. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec 15; 147(51-52):69. PubMed ID: 16402717
    [No Abstract] [Full Text] [Related]

  • 13. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
    Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaró J, Roget M, García I, Pedrol E, Tor J, Ballesteros AL, Salas A, Sirera G, Videla S, Clotet B, Tural C.
    Antivir Ther; 2006 Dec 15; 11(4):473-82. PubMed ID: 16856621
    [Abstract] [Full Text] [Related]

  • 14. Hepatitis C cure after 6 months of telaprevir-based therapy in an HIV-infected man.
    Cachay ER.
    Clin Infect Dis; 2013 Jan 15; 56(1):163-4. PubMed ID: 23001703
    [No Abstract] [Full Text] [Related]

  • 15. Interferon for hepatitis C patients with psychiatric disorders.
    Rifai MA, Bozorg B, Rosenstein DL.
    Am J Psychiatry; 2004 Dec 15; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
    [No Abstract] [Full Text] [Related]

  • 16. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M, Morlat P, Bonnet F, Rambeloarisoa J, Bernard N, Lacoste D, Bonarek M, Trimoulet P, Ramanampamonjy R, Lafon ME, Dramé M, Beylot J.
    Rev Med Interne; 2005 Apr 15; 26(4):280-7. PubMed ID: 15820563
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B, CORAL-1 study group.
    J Viral Hepat; 2007 Oct 15; 14(10):704-13. PubMed ID: 17875005
    [Abstract] [Full Text] [Related]

  • 18. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C.
    J Viral Hepat; 2008 Jul 15; 15(7):482-9. PubMed ID: 18221297
    [Abstract] [Full Text] [Related]

  • 19. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
    Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S.
    Hepatology; 2003 Jun 15; 37(6):1351-8. PubMed ID: 12774014
    [Abstract] [Full Text] [Related]

  • 20. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M.
    Hepatology; 2007 Jan 15; 45(1):258-9. PubMed ID: 17187414
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.